Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Recent study

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Oct 08, 2022 12:06pm

219 Views

Post# 35014046

RE:RE:RE:Recent study

That would be an amazing story! Even if nothing much ever comes of our investment in TH, I hope at least something like TH-1902 being a solution for your cancer is one of the rewards for our patience. I am hoping you will be healed before TH-1902 makes it to a place where it is a possibility for you but whatever way you put cancer behind you for good is a win - the sooner the better!

jfm1330 wrote: Another reference confirms that sortilin is overexpressed and involved in neuroendocrine tumors and metastasis of these tumors. Good for me to read that, hope for the future. Imagine being saved at some point in time y the company I was invested in. It would be an amazing story.

The article also confirms overexpression of sortilin in aggressive prostate cancers, which is good for us to know considering the results of phase Ia. This article also confirms what I was talking about the other day, sortilin is found in the membranes of the Golgi apparatus and the endoplasmic reticulum, which could explain why through endosome internalization TH1902 can bypass efflux pump. Also, Golgi and ER are involved with tubulin, the protein that docetaxel is interacting with.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884004/

Wino115 wrote: Great find. Ours boys research is mentioned twice - footnotes 38 and 88. Getting some recognition for the PDC and sort1 target!

jeffm34 wrote: https://mdpi-res.com/d_attachment/ijms/ijms-23-11888/article_deploy/ijms-23-11888.pdf?version=1665063006